Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

SLE decreases risk for hormonal cancers. by Deborah K. Johnson (10001156)

“…<p>Odds ratios (OR) and 95% confidence intervals of SLE and MS cohorts. For all graphs, the dotted line represents an OR of 1.0. …”

Downregulation of DOM decreases the abundance of PER and TIM. by Zhenxing Liu (399809)

“…Downregulation of DOM decreased PER levels at CT1-5 and CT17-21. (Scale bar: 50 um.) …”

An increase in MOI decreases neuronal dendrite numbers. by Emily Z. Tabaie (16630841)

DART-ID decreases missing datapoints across runs. by Albert Tian Chen (6900215)

“…Only peptides seen in >50% of experiments are included. (<b>b</b>) Decrease in missing data across all runs after applying DART-ID, for SCoPE-MS and the two bulk sets from <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1007082#pcbi.1007082.g004" target="_blank">Fig 4</a> at 1% FDR. …”

mGluR5 receptor decreased glycinergic currents. by Zi-Yang Zhang (4988555)

“…(<b>E</b>) The inhibitory effect of CHPG on GlyR-IPSCs was not blocked by intracellularly loaded GDP-β-S (62.3 ± 6.4% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.782, <i>p</i> = 0.032), chelerythrine (60.9 ± 11.3% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.705, <i>p</i> = 0.035), or Ro-32-0432 (69.9 ± 3.2% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 8.495, <i>p</i> < 0.001). (<b>F</b>) Postsynaptic loading of U-0126 or PD98059 prevented CHPG from decreasing glycinergic responses (U-0126, 107.6 ± 10.4% of baseline at 15–20 min post-CHPG, <i>t</i>[8] = 0.997, <i>p</i> = 0.348; PD98059, 93.1 ± 5.0% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 0.883, <i>p</i> = 0.418). …”

Bacterial co-abundance networks decreases in complexity with lower host genetic variation. by Michael Ørsted (5926028)

Probability of release is decreased by hydrophobic mutations. by Matthew R. Bowers (8423115)

SARS-CoV-2 induced lung inflammation is increased with IL-10 blockade and decreased with IFNγ blockade. by Christine E. Nelson (18946410)

Repetitive stress induces a decrease in sound-evoked activity. by Ghattas Bisharat (20706928)

“…Activity rates decreased during repeated stress compared to baseline (2-way ANOVA, condition F = 185.6, <i>p</i> = 4.8 × 10⁻⁴², condition: intensity interaction F = 10.37, <i>p</i> = 9.3 × 10⁻²¹, nested ANOVA (mouse nested within session), condition F = 174, <i>p</i> = 1.5 × 10⁻³⁹, condition: intensity interaction F = 12.7, <i>p</i> = 2 × 10⁻²⁶, post hoc for each level baseline versus repetitive stress <i>p</i> < 0.01 for all levels above 50 dB, all Bonferroni corrected). …”

Juvenile demyelination leads to a decrease in axonal complexity of PFC PV interneurons. by Sara Hijazi (21656615)

“…The number of branch points in PV interneuron axons from cuprizone-treated mice was significantly decreased compared to control mice (<i>t test; n = 10/9 cells per group, *p < 0.05</i>). …”

Decreased type I IFN response in B cells carrying the MS-protective class I alleles. by Christian Lundtoft (4068679)

PNs, ORNs and LNs response to a short (50 ms) pulse, similar results of Fig 4. by Mario Pannunzi (553941)

Data_Sheet_1_Switching to second line MS disease-modifying therapies is associated with decreased relapse rate.PDF by James John Marriott (16935942)

Germ cell size decreases before corpse formation. by Tea Kohlbrenner (19476160)

Decrease in vRNA in brain during antiretroviral therapy. by Sonny R. Elizaldi (9684796)

HFD induces LDs and decreases ER and mitochondria in nephrocytes. by Aleksandra Lubojemska (10746241)

“…(<b>E</b>) Low and high magnification views of pericardial nephrocytes (dotted outlines) from STD and HFD larvae, showing that HFD decreases mitochondria (marked with anti-ATP5A) and ER (marked with anti-KDEL) but increases LDs (marked with LipidTOX). …”

PI+ CD3+ T cells decrease at day 14 after IR while PI+ CD3- cells decrease at all time points. by Jordan A. Gunning (18143970)

Subjects:

M344 decreases orthotopic pancreatic tumor growth when used as a treatment alone or in combination with gemcitabine. by Shelby M. Knoche (13833807)

Cell growth and viability decrease confirmed by growth inhibition in HepG3. by Arlet Hernandez (12289155)